New-generation proton pump inhibitors: Overcoming the limitations of early-generation agents

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue SUPPL. 1, 2001, Pages

  Robinson, M ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Esomeprazole; GORD; Lansoprazole; Omeprazole; Proton pump inhibitor; Rabeprazole

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROTON PUMPS;

EID: 0034958073     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Critical issues in the management of gastroesophageal reflux disease
2. The rationale for continuous maintenance treatment of reflux esophagitis
3. Acid reduction in peptic ulcer disease: Choosing therapy according to drug interactions, individual response, and cost
4. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
5. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
6. Shortcomings of the first-generation proton pump inhibitors
7. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
8. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease
9. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease
10. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents
11. Identification of the characteristics influencing the degree of antisecretory activity of PPIs
12. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg
13. Significant heartburn relief after the first dose of rabeprazole sodium in non-erosive reflux disease (NERD) patients
14. Rabeprazole 20 mg in the Future of Acid Suppression Therapy (F.A.S.T.) Trial with rabeprazole: Acute heartburn relief in patients refractory to omeprazole and lansoprazole
15. Esomeprazole is superior to omeprazole for the healing of erosive esophagitis in GERD patients
16. Pharmacological management of gastro-oesophageal reflux disease
17. Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders
18. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole
19. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans
20. Omeprazole metabolism in patients with refractory gastroesophageal reflux
21. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole
22. Drug-drug interaction evaluation of rabeprazole sodium: A clean/expected slate?